NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
NBIX on Nasdaq
Shares outstanding
99,605,545
Price per share
$141.83
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
96,836,176
Total reported value
$13,589,141,149
% of total 13F portfolios
0.01%
Share change
-2,213,075
Value change
-$269,540,402
Number of holders
636
Price from insider filings
$141.83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 12% $1,095,189,866 12,052,271 BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 10% $920,484,658 10,129,687 The Vanguard Group 28 Feb 2025
DODGE & COX 5.6% $502,931,283 5,534,624 Dodge & Cox 31 Mar 2025
STATE STREET CORP 4.8% $444,457,619 4,891,137 STATE STREET CORPORATION 31 Dec 2024

As of 30 Sep 2025, 636 institutional investors reported holding 96,836,176 shares of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX). This represents 97% of the company’s total 99,605,545 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) together control 65% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 12,706,230 -1.9% 0.03% $1,783,700,523
VANGUARD GROUP INC 9.7% 9,706,559 -1% 0.02% $1,362,606,752
Dodge & Cox 5.6% 5,556,618 -0.18% 0.42% $780,038,035
JPMORGAN CHASE & CO 4.7% 4,730,152 +11% 0.04% $664,018,845
STATE STREET CORP 4.4% 4,346,479 -2.7% 0.02% $610,158,722
PRICE T ROWE ASSOCIATES INC /MD/ 2.9% 2,866,731 -7.1% 0.04% $402,433,000
AQR CAPITAL MANAGEMENT LLC 2.8% 2,773,648 +84% 0.25% $388,435,470
RENAISSANCE TECHNOLOGIES LLC 2.4% 2,418,297 +2.2% 0.45% $339,480,533
GEODE CAPITAL MANAGEMENT, LLC 2% 2,024,825 +3.3% 0.02% $283,499,084
MORGAN STANLEY 1.8% 1,826,936 +0.4% 0.02% $256,465,385
WELLINGTON MANAGEMENT GROUP LLP 1.8% 1,811,762 -11% 0.04% $254,335,149
Bellevue Group AG 1.8% 1,763,105 -3.1% 5.1% $247,504,680
LOS ANGELES CAPITAL MANAGEMENT LLC 1.2% 1,202,756 +62% 0.57% $168,842,887
DEERFIELD MANAGEMENT COMPANY, L.P. 1.2% 1,184,345 +1.4% 2.5% $166,258,351
RTW INVESTMENTS, LP 1.1% 1,062,072 0% 1.8% $149,093,667
MILLENNIUM MANAGEMENT LLC 0.98% 977,210 -18% 0.11% $137,180,740
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 0.95% 948,033 -8.2% 0.35% $133,038,000
NORTHERN TRUST CORP 0.93% 925,714 -0.36% 0.02% $129,951,731
BRAIDWELL LP 0.88% 880,282 -24% 3.7% $123,573,987
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.83% 829,547 +5% 0.02% $116,451,808
CITADEL ADVISORS LLC 0.8% 793,239 -61% 0.09% $111,354,891
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 0.77% 765,237 -45% 0.02% $107,423,971
Bank of New York Mellon Corp 0.76% 761,396 -2.2% 0.02% $106,884,718
DIMENSIONAL FUND ADVISORS LP 0.71% 710,122 +3.8% 0.02% $99,685,572
BANK OF AMERICA CORP /DE/ 0.71% 704,254 +7.8% 0.01% $98,863,177

Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 382,206 $53,874,992 +$26,484,758 $141.83 27
2025 Q3 96,836,176 $13,589,141,149 -$269,540,402 $140.38 636
2025 Q2 98,821,223 $12,420,454,326 +$494,179,758 $125.69 579
2025 Q1 95,417,971 $10,551,945,421 +$6,531,028 $110.60 576
2024 Q4 94,333,748 $12,873,973,627 +$277,419,295 $136.50 589
2024 Q3 92,618,112 $10,675,977,715 -$220,711,285 $115.22 567
2024 Q2 93,723,042 $12,899,413,706 +$111,362,329 $137.67 588
2024 Q1 92,893,700 $12,808,484,013 +$99,362,674 $137.92 578
2023 Q4 340,874 $44,922,763 -$4,661,614 $131.76 10
2023 Q3 91,624,177 $10,307,754,453 +$19,999,748 $112.50 498
2023 Q2 89,622,581 $8,456,259,836 +$8,430,809 $94.30 441
2023 Q1 90,680,694 $9,172,726,038 +$82,697,429 $101.22 472
2022 Q4 89,773,715 $10,712,889,415 +$124,934,670 $119.44 517
2022 Q3 89,171,673 $9,470,813,485 -$94,873,044 $106.21 441
2022 Q2 88,899,211 $8,661,032,375 -$6,400,984 $97.48 413
2022 Q1 86,505,431 $8,107,722,582 +$147,175,305 $93.75 401
2021 Q4 88,879,779 $7,563,734,979 -$135,795,395 $85.17 383
2021 Q3 89,939,974 $8,626,841,425 -$73,045,846 $95.91 381
2021 Q2 91,200,454 $8,874,238,168 -$391,326,180 $97.32 394
2021 Q1 94,776,648 $9,211,930,058 +$550,111,004 $97.25 404
2020 Q4 89,345,265 $8,564,242,432 -$6,526,498 $95.85 385
2020 Q3 88,443,291 $8,503,707,342 -$165,682,314 $96.16 399
2020 Q2 90,807,745 $11,093,067,640 +$57,420,368 $122.00 404
2020 Q1 90,430,403 $7,829,376,352 +$141,657,290 $86.55 353
2019 Q4 88,845,101 $9,547,614,883 -$105,647,998 $107.49 379
2019 Q3 89,544,054 $8,067,789,696 +$131,855,532 $90.11 320
2019 Q2 88,851,615 $7,501,057,970 +$476,297,870 $84.43 293
2019 Q1 88,273,975 $7,776,692,330 -$77,116,522 $88.10 318
2018 Q4 89,470,402 $6,374,594,256 -$87,239,322 $71.41 318
2018 Q3 88,623,711 $10,894,004,580 -$352,121,911 $122.95 337
2018 Q2 91,100,517 $8,948,547,815 +$108,689,438 $98.24 269
2018 Q1 92,034,159 $7,632,271,781 -$152,719,450 $82.93 258
2017 Q4 89,063,885 $6,910,330,345 -$127,768,371 $77.59 255
2017 Q3 95,975,362 $5,879,197,865 +$103,868,412 $61.28 219
2017 Q2 94,854,499 $4,360,456,382 +$625,150,488 $46.00 219
2017 Q1 84,832,216 $3,672,689,679 +$229,920,607 $43.30 212
2016 Q4 84,113,039 $3,255,240,619 -$79,497,227 $38.70 217
2016 Q3 85,700,381 $4,337,544,435 +$54,775,049 $50.64 235
2016 Q2 84,771,135 $3,855,815,900 -$118,002,301 $45.45 223
2016 Q1 87,598,920 $3,462,559,615 +$138,148,038 $39.55 208
2015 Q4 83,395,854 $4,717,623,664 +$48,341,852 $56.57 215
2015 Q3 82,777,737 $3,293,072,792 -$26,817,694 $39.79 202
2015 Q2 82,282,268 $3,929,380,654 -$83,608,659 $47.76 193
2015 Q1 85,169,622 $3,379,999,692 +$405,560,732 $39.71 170
2014 Q4 75,151,640 $1,678,834,423 +$53,080,878 $22.34 131
2014 Q3 73,295,238 $1,148,500,395 +$44,837,828 $15.67 132
2014 Q2 70,371,932 $1,044,160,097 +$24,609,151 $14.84 123
2014 Q1 69,736,034 $1,122,530,688 +$194,807,523 $16.10 121